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2 infections, p¼0.0001). Infection incidence was signiﬁ-
cantly increased in patients receiving ATG compared to
those not receiving ATG (median 3 vs. 2, p¼0.0003). The
relative increase in infections with ATG was more pro-
nounced in RIC (+ATG median 3 vs eATG median 1) than in
MAC (+ATG median 4 vs. eATG median 3). In both RIC and
MAC, ATG use was associated with increased numbers of
CMV (112 vs. 61), HHV6 (47 vs. 13), and HSV (32 vs. 8)
infections. The relative increase in infection incidence for
+ATG patients in RIC (CMV 2.5-fold, HHV6 10.5-fold, HSV
6.5-fold increase) was greater than the increase seen for
+ATG patients in MAC (CMV 1.46-fold, HHV6 2.36-fold, HSV
3.17-fold increase).
Similar rates of severe (grade 3-4) aGVHD were observed
in +ATG patients compared to eATG patients (17.5% vs.
14.95%, p¼0.72) through day 180, indicating a potential
protective effect of ATG in unrelated/mismatched trans-
plants. In RIC, a nonsigniﬁcantly greater proportion of +ATG
patients developed severe aGVHD (19.4%) compared toeATG
patients (12.9%).
The rates of relapse/death were not different between
ATG groups (29.91% for eATG and 39.68% for +ATG), and
groups had similar mean times to relapse (148 days foreATG
and 138 days for +ATG). At 180 days, survival was 83.2% for
eATG and 71.4% for +ATG (p¼0.0426).
Conclusion: Our study demonstrates that ATG use in-
creases infection rates in alloHCT patients, with greater
impact in the RIC setting. Although relapse rates were
similar between groups, the 180-day mortality for +ATG
was signiﬁcantly greater than eATG, suggesting that in-
fectious complications may impact mortality associated
with ATG.Figure 2. Time to relapse126
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Background: Current literature supports the use of he-
matopoietic stem cell transplants (hSCT) over salvage
chemotherapy for patients with lymphoma who have
recurrent disease or are at high risk of relapse. Few studies
have been published directly comparing preparative regi-
mens, thus most institutions select regimens based on
associated toxicities. At our institution, Busulfan/Cyclo-
phosphamide (Bu-Cy) was historically used as the prepar-
ative regimen for patients with lymphoma. A transition was
made in 2009 to favor the theoretically less toxic Carmus-
tine/Etoposide/Cyclophosphamide (CBV) regimen for older
patients.
Objective: Compare the tolerability and efﬁcacy of Bu-Cy and
CBV as they pertain to autologous stem cell transplants in
older patients.
Methods: We report a retrospective review of institutional
data evaluating the safety and efﬁcacy of Bu-Cy and CBV in
patients with lymphoma receiving an autologous hSCT be-
tween January 2005 and January 2014. Patients were
excluded if they were less than 60 years of age. The primary
outcomewas the incidence of grade 3 and 4 toxicities per theCTCAE v4.03. Secondary outcomes included progression-free
and overall survival.
Results: Seventy-ﬁve patients were available for analysis,
23 received Bu-Cy and 52 received CBV. Patients who
received Bu-Cy experienced an average of 1.6 severe or life-
threatening toxicities per patient compared with 1.7 for
those who received CBV. There was no difference in pro-
gression-free (BuCy 86% vs CBV 95%) or overall survival
(BuCy 96% vs CBV 94%) at 60 days; however, there was a
trend toward increased progression-free survival (BuCy31%
vs CBV 68%) at three years Figure 1) and this trend was
supported by the increased time to relapse (BuCy 22.7 vs
CBV 61.2 months) (Figure 2).
Conclusions: This review demonstrates no difference in
terms of tolerability or efﬁcacy between Bu-Cy and CBV;
however, there is a trend towards improved relapse free
survival with CBV. Future studies are needed to compare
other utilized preparative regimens.127
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